Drug resistance remains a major challenge in cancer treatment. While single-cell profiling offers unprecedented resolution for uncovercovering resistance mechanisms, the potential of emerging ...
Transcriptomic assays such as the PAM50-based ROR-P score guide recurrence risk stratification in non-metastatic, ER-positive, HER2-negative breast cancer but are not universally accessible.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results